FaribaNavidMD
Pediatric Hematology & Oncology • Los Angeles, CAAssociate Professor, Pediatrics, University of Tennessee Health Science Center College of Medicine
Are you Dr. Navid?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 84 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
4650 W Sunset Blvd
Los Angeles, CA 90027Phone+1 323-361-4100Fax+1 323-361-3642- Is this information wrong?
Summary
- Dr. Fariba Navid, MD is a pediatric hematologist/oncologist in Los Angeles, California. She is currently licensed to practice medicine in California, Tennessee, and Maryland. She is affiliated with Children's Hospital Los Angeles and is an Associate Professor at University of Tennessee Health Science Center College of Medicine.
Education & Training
National Capital ConsortiumFellowship, Pediatric Hematology/Oncology, 1994 - 1997
Case Western Reserve Univ/Univ Hosps Cleveland Med Ctr/Rainbow Babies and Childrens HospitalResidency, Pediatrics, 1989 - 1993
Tulane University School of MedicineClass of 1989
Certifications & Licensure
CA State Medical License 2016 - 2026
TN State Medical License 2002 - 2016
VA State Medical License 1993 - 2004
MD State Medical License 1993 - 2003
OH State Medical License 1992 - 1994
LA State Medical License 1989 - 1994- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Osteosarcoma1999-A Study Of Intensive Chemotherapy for Osteosarcoma Start of enrollment: 1999 May 01
- Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma Start of enrollment: 2008 May 09
- Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia Start of enrollment: 2007 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- An Exome Capture-Based RNA-Sequencing Assay for Genome-Wide Identification and Prioritization of Clinically Important Fusions in Pediatric Tumors.Buckley, J., Schmidt, R., Ostrow, D., Maglinte, D., Bootwalla, M., Ruble, D., Govindarajan, A., Ji, J., Kovach, A., Orgel, E., Raca, G., Navid, F., Mascarenhas, L., Pa...> ;The Journal of Molecular Diagnostics. 2024 Feb 1
- Survival outcomes and surgical morbidity based on surgical approach to pulmonary metastasectomy in pediatric, adolescent and young adult patients with osteosarcoma.Christopher Kuo, Jemily Malvar, Yueh-Yun Chi, Eugene S Kim, Rachana Shah, Fariba Navid, James E Stein, Leo Mascarenhas> ;Cancer Medicine. 2023 Oct 1
- 3 citationsPhase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma.Srivandana Akshintala, R Taylor Sundby, Donna Bernstein, John W Glod, Rosandra N Kaplan, Marielle E Yohe, Andrea M Gross, Joanne Derdak, Haiyan Lei, Alexander Pan, Eva...> ;Clinical Cancer Research. 2023 Sep 1
- Join now to see all
Press Mentions
- Children’s Hospital Los Angeles Develops Liquid Biopsy Test for Pediatric Solid TumorsMarch 2nd, 2023
- Liquid Biopsy Test for Children’s Solid Tumors DevelopedMarch 2nd, 2023
Professional Memberships
- Member
Hospital Affiliations
Children's Hospital Los AngelesLos Angeles, California
